Pasireotide

CAS No. 396091-73-9

Pasireotide( SOM 230 | SOM 320 )

Catalog No. M14362 CAS No. 396091-73-9

A potent, stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Pasireotide
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors.
  • Description
    A potent, stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (pKi=8.2/9.0/9.1/<7.0/9.9 for sst1/2/3/4/5, respectively); effectively inhibits GHRH-induced growth hormone release in primary cultures of rat pituitary cells with IC50 of 0.4 nM, also potently suppresses GH secretion in rats.Cushing's Disease Approved.
  • In Vitro
    Pasireotide exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively).Pasireotide effectively inhibits the growth hormone releasing hormone (GHRH) induced growth hormone (GH) release in primary cultures of rat pituitary cells, with an IC50 of 0.4 nM.
  • In Vivo
    Pasireotide (160 mg/kg/mouth; s.c. for 4 months) significantly decreases the serum insulin, increases serum glucose, reduces the tumor size and increases apoptosis in Pdx1-Cre.Pasireotide (2-50 μg/kg; s.c. twice daily for 42 days) exerts the antinociceptive and antiinflammatory actions via the SSTR2 receptor in a mouse model of immune-mediated arthritis. Animal Model:12 month-old conditional Men1 knockout mice with insulinoma Dosage:160 mg/kg/mouth Administration:S.c. every month for 4 monthsResult:Decreased the serum insulin from 1.060 μg/L to 0.3653 μg/L and increased the serum glucose from 4.246 mM to 7.122 mM.Significantly reduced the tumor size and increased apoptosis.
  • Synonyms
    SOM 230 | SOM 320
  • Pathway
    GPCR/G Protein
  • Target
    Somatostatin Receptor
  • Recptor
    Somatostatin Receptor
  • Research Area
    Endocrinology
  • Indication
    Cushing Disease

Chemical Information

  • CAS Number
    396091-73-9
  • Formula Weight
    1047.206
  • Molecular Formula
    C58H66N10O9
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN
  • Chemical Name
    Cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-(phenylmethyl)-L-tyrosyl-L-phenylalanyl-(4R)-4-[[[(2-aminoethyl)amino]carbonyl]oxy]-L-prolyl]

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Lewis I, et al. J Med Chem. 2003 Jun 5;46(12):2334-44. 2. Bruns C, et al. Eur J Endocrinol. 2002 May;146(5):707-16. 3. Hofland LJ, et al. Eur J Endocrinol. 2005 Apr;152(4):645-54.
molnova catalog
related products
  • Octreotide acetate

    An octapeptide that mimics natural somatostatin pharmacologically, that is 200 times more potent than somatostatin.

  • Somatostatin-28 1-14

    Somatostatin-28 (1-14) is an N-terminal fragment of the neuropeptide somatostatin-28. Somatostatin 28 arises from the posttranslational cleavage of prosomatostatin, which in turn is derived from a large precursor, preprosomatostatin.

  • CYN 154806 TFA

    CYN 154806 TFA is a cyclic octapeptide and an effective selective somatostatin sst2 receptor antagonist. For the recombinant sst2, sst1, sst3, sst4 and sst5 receptors, the pIC50 values are 8.58, 5.41, 6.07, 5.76 and 6.48, respectively.